We are live on ! Find out more
EWTX icon

Edgewise Therapeutics

173 hedge funds and large institutions have $1.82B invested in Edgewise Therapeutics in 2025 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 58 increasing their positions, 62 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

90% more call options, than puts

Call options by funds: $3.84M | Put options by funds: $2.02M

17% more capital invested

Capital invested by funds: $1.56B → $1.82B (+$259M)

6% less repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 62

3% less funds holding

Funds holding: 178173 (-5)

6.59% less ownership

Funds ownership: 112.87%106.28% (-6.6%)

22% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 23

25% less funds holding in top 10

Funds holding in top 10: 86 (-2)

Holders
173
Holders Change
-5
Holders Change %
-2.81%
% of All Funds
2.27%
Holding in Top 10
6
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-25%
% of All Funds
0.08%
New
18
Increased
58
Reduced
62
Closed
23
Calls
$3.84M
Puts
$2.02M
Net Calls
+$1.82M
Net Calls Change
+$2.2M
Name Holding Trade Value Shares
Change
Change in
Stake
Artisan Partners
26
Artisan Partners
Wisconsin
$11.6M -$9.37M -660,893 -48%
D.E. Shaw & Co
27
D.E. Shaw & Co
New York
$11M +$1.16M +82,129 +14%
Aberdeen Group
28
Aberdeen Group
United Kingdom
$10.1M +$2.5M +176,559 +40%
Charles Schwab
29
Charles Schwab
California
$9.69M +$262K +18,499 +3%
Northern Trust
30
Northern Trust
Illinois
$9.54M -$213K -15,016 -2%
EAM
31
Eventide Asset Management
Massachusetts
$9.22M
Qube Research & Technologies (QRT)
32
Qube Research & Technologies (QRT)
United Kingdom
$9.01M +$791K +55,796 +11%
PHP
33
Parkman Healthcare Partners
Connecticut
$8.92M -$1.38M -97,158 -15%
Citigroup
34
Citigroup
New York
$8.73M -$2.64M -186,446 -26%
Goldman Sachs
35
Goldman Sachs
New York
$8.56M -$1.47M -103,916 -16%
SI
36
Sofinnova Investments
California
$8.44M -$2.79M -196,633 -27%
EP
37
Eversept Partners
New York
$8.15M +$1.55M +109,495 +28%
OM
38
Opaleye Management
Massachusetts
$8.11M +$142K +10,000 +2%
Victory Capital Management
39
Victory Capital Management
Texas
$8.09M +$792K +55,809 +13%
TCM
40
Tang Capital Management
California
$7M
GIM
41
Granahan Investment Management
Massachusetts
$5.51M -$934K -65,861 -16%
Bank of America
42
Bank of America
North Carolina
$5.21M +$946K +66,703 +26%
SCM
43
Sio Capital Management
New York
$4.98M -$3.3M -232,549 -43%
KCM
44
Kynam Capital Management
New Jersey
$4.12M
Fidelity Investments
45
Fidelity Investments
Massachusetts
$4.11M -$3.08M -217,392 -46%
KCM
46
Kennedy Capital Management
Missouri
$4.07M -$27K -1,902 -0.8%
Barclays
47
Barclays
United Kingdom
$3.81M -$661K -46,600 -17%
WP
48
Woodline Partners
California
$3.64M -$12.4M -872,673 -80%
CS
49
Candriam SCA
Luxembourg
$3.59M -$40.2K -2,831 -1%
Neuberger Berman Group
50
Neuberger Berman Group
New York
$3.56M +$768K +54,111 +33%

EWTX Hedge Fund Activity: Q3 2025 in Review

173 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Edgewise Therapeutics (EWTX) for Q3 2025, worth a combined $1.82B — up 17% from $1.56B a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of EWTX and 18 opened new positions — a net loss of 5 holders — while 62 trimmed existing stakes and 58 added.

The largest buyer was Siren LLC, adding an estimated $10.5M. The largest seller was Deerfield Management, cutting an estimated $18.5M.

  • 173 institutional investors held Edgewise Therapeutics (EWTX) as of Q3 2025, down from 178 in Q2 2025.
  • Funds reported $1.82B of Edgewise Therapeutics stock for Q3 2025, up 17% quarter-over-quarter.
  • 18 funds opened new Edgewise Therapeutics positions in Q3 2025 and 23 closed out, a net change of -5 holders.
  • The largest Edgewise Therapeutics buyer in Q3 2025 was Siren LLC, an estimated $10.5M added.
  • The largest Edgewise Therapeutics seller in Q3 2025 was Deerfield Management, an estimated $18.5M sold.

Based on aggregated 13F filings for Q3 2025.